Timothy Peters-Strickland, MD

  • 2Articles
  • 18.5KReads
  • 2014–2022Active
  • 19Collaborators
  • 101Citations

About

Timothy Peters-Strickland, MD, is affiliated with Otsuka Pharmaceutical Development & Commercialization, Inc. in Princeton, New Jersey. His publications focus on schizophrenia and schizoaffective disorders, including clinical trials evaluating aripiprazole once-monthly for acute treatment and the impact of a digital medicine system on psychiatric hospitalization rates. Peters-Strickland has contributed to research published between 2014 and 2022 in Psychiatrist.com.

Publications

JCP
Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia
Original Research

Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia

April 11, 2022

This clinical trial investigated whether hospitalization rates improved when patients with schizophrenia were treated via a digital medicine system (aripiprazole tablets with sensor) versus oral standard-of-care therapy.
, , , et al
JCP
Original Research

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

August 19, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe